Artritis idiopática juvenil

Bibliografía:

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369:767–78.
2. Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52:2092–102.
3. Duffy CM. Health outcomes in pediatric rheumatic diseases. Curr Opin Rheumatol. 2004; 16:102–8.
4. Passo MH, Taylor J. Quality improvement in pediatric rheumatology: what do we need to do? Curr Opin Rheumatol. 2008; 20:625–30.
5. Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, et al. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011; 63:10–6.
6. Brunner HI, Ravelli A. Developing outcome measures for paediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2009; 23:609–24.
7. Luca NJ, Feldman BM. Health outcomes of pediatric rheumatic diseases. Best Pract Res Clin Rheumatol. 2014; 28:331–50.
8. Duffy CM. Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Pediatr Clin North Am. 2005; 52:359–72. .
9. Brunner HI, Giannini EH. Health-related quality of life in children with rheumatic diseases. Curr Opin Rheumatol. 2003; 15:602–12.
10. Feldman BM, Grundland B, McCullough L, Wright V. Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol. 2000; 27:226–33.
11. Berard R, Laxer RM. Improving the quality of care in children with juvenile idiopathic arthritis: a step in the right direction. J Rheumatol. 2011; 38:789–90.
12. McErlane F, Beresford MW, Baildam EM, Thomson W, Hyrich KL. Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. Rheumatol. 2013; 52:1941–51.
13. Filocamo G, Consolaro A, Solari N, Palmisani E, Dalprà S, et al. Recent advances in quantitative assessment of juvenile idiopathic arthritis. Ann Paediatr Rheumatol. 2012; 1:84–96.
14. Ravelli A. The JADAS: A Simple and Reliable Tool for the Measurement of Disease Activity in Juvenile Idiopathic Arthritis. Ann Paediatr Rheum. 2014; 3:1–3.
15. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009; 61:658–66.
16. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997; 40:1202–9.
17. Palmisani E, Solari N, Magni-Manzoni S, Pistorio A, Labo E, Panigada S, et al. Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. Arthritis Rheum. 2006; 55:843–9.
18. Filocamo G, Davi S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-cm horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010; 37:1534–41.
19. Bazso A, Consolaro A, Ruperto N, Pistorio A, Viola S, Magni-Manzoni S, et al. Development and testing of reduced joint counts in juvenile idiopathic arthritis. J Rheumatol. 2009; 36:183–90.
20. Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis. 2012; 71: 1122–7.
21. McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013; 72:1983–8.
22. Consolaro A, Negro G, Gallo MC, Bracciolini G, Ferrari C, Schiappapietra B et al. Defining criteria for disease activity states in non-systemic juvenile idiopathic arthritis based on a three-variable Juvenile Arthritis Disease Activity Score. Arthritis Care Res (Hoboken). 2014; 66:1703–9.
23. Weiss PF, Colbert RA, Xiao R, Feudtner C, Beukelman T, DeWitt EM, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res (Hoboken). 2014; 66:1775–82.
24. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005; 52:2625–36.
25. Filocamo G, Consolaro A, Schiappapietra B, Dalpra S, Lattanzi B, Magni- Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol. 2011; 38:938–53.
26. Consolaro A, Bracciolini G, Ruperto N, Pistorio A, Magni-Manzoni S, Malattia C, et al. Remission, minimal disease activity and acceptable symptom state in juvenile idiopathic arthritis. Arthritis Rheum. 2012; 64:2366–74.
27. Consolaro A, Ruperto N, Bracciolini G, Frisina A, Gallo MC, Pistorio A, et al. Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. Ann Rheum Dis. 2014; 73:1380–3.
28. Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004; 31:2290–4.
29. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011; 63:929–36.
30. Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2008; 59:1120–7.
31. Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol. 2002; 29:1058–64.
32. Lovell DJ, Ruperto N, Giannini EH, Martini A. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013; 9:557–63.
33. de Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012; 367:2385–95.
34. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012; 367:2396–406.
35. Horneff G, Becker I. Definition of improvement in juvenile idiopathic arthritis using the Juvenile Arthritis Disease Activity Score. Rheumatology (Oxford). 2014; 53:1229–34.
36. Luca NJ, Feldman BM. Disease activity measures in paediatric rheumatic diseases. Int J Rheumatol. 2013; 2013:715352.
37. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294:1671–84.
38. Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2009; 11:216.
39. Ruperto N, Martini A. Emerging drugs to treat juvenile idiopathic arthritis. Expert Opin Emerg Drugs. 2011; 16:493–505.
40. Wallace CA, Huang B, Bandeira M, Ravelli A, Giannini EH. Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52:3554–62.
41. Ravelli A, Martini A. Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2006; 24:S105–10.
42. Martini A, Lovell DJ. Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis. 2010; 69:1260–3.
43. Magnani A, Pistorio A, Magni-Manzoni S, Falcone A, Lombardini G, Bandeira M, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol. 2009; 36:628–34.
44. Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treatto- target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012; 30:S157–62.
45. Wells G, Boers M, Shea B, Anderson J, Felson D, Johnson K, et al. MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. J Rheumatol. 2003; 30:1110–1.
46. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004; 364:263–9.
47. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van ZD, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2008; 58:S126–35.
48. Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol. 2003; 21:S209–10.
49. Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet. 2009; 374:430–2.
50. Bartoli M, Taro M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2008; 67:370–4.
51. Consolaro A, Vitale R, Pistorio A, Lattanzi B, Ruperto N, Malattia C, et al. Physicians’ and parents’ ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. J Rheumatol. 2007; 34:1773–6.
52. Luca N, Feldman BM. Pediatric rheumatology: Improving the assessment of children with JIA. Nat Rev Rheumatol. 2011; 7:442–4.
53. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994; 37:1761–9.
54. Apaz MT, Saad-Magalhaes C, Pistorio A, Ravelli A, de Oliveira SJ, Marcantoni MB, et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum. 2009; 61:509–17.
55. Duffy CM, Arsenault L, Duffy KN, Paquin JD, Strawczynski H. The Juvenile Arthritis Quality of Life Questionnaire—development of a new responsive index for juvenile rheumatoid arthritis and juvenile spondyloarthritides. J Rheumatol. 1997; 24:738–46.
56. Varni JW, Seid M, Smith KT, Burwinkle T, Brown J, Szer IS. The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module. Arthritis Rheum. 2002; 46:714–25.
57. Filocamo G, Sztajnbok F, Cespedes-Cruz A, Magni-Manzoni S, Pistorio A, Viola S, et al. Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis Rheum. 2007; 57:913–20.
58. Filocamo G, Schiappapietra B, Bertamino M, Pistorio A, Ruperto N, Magni- Manzoni S, et al. A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. Rheumatology (Oxford). 2010; 49:1272–80.
59. Gong GW, Young NL, Dempster H, Porepa M, Feldman BM. The Quality of My Life questionnaire: the minimal clinically important difference for pediatric rheumatology patients. J Rheumatol. 2007; 34:581–7.
60. Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W, Hoppenreijs EP, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum. 2011; 63:2007–13.
61. Reeve BB, Hays RD, Bjorner JB, Cook KF, Crane PK, Teresi JA, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007; 45:S22–31.
62. Jacobson CJ, Farrell JE, Kashikar-Zuck S, Seid M, Verkamp E, DeWitt EM. Disclosure and self-report of emotional, social, and physical health in children and adolescents with chronic pain—a qualitative study of PROMIS pediatric measures. J Pediatr Psychol. 2013;38:82–93.
63. Dewalt DA, Rothrock N, Yount S, Stone AA. Evaluation of item candidates: the PROMIS qualitative item review. Med Care. 2007; 45:S12–21.
64. Kashikar-Zuck S, Carle A, Barnett K, Goldschneider KR, Sherry DD, Mara CA, et al. Longitudinal evaluation of patient-reported outcomes measurement information systems measures in pediatric chronic pain. Pain. 2016; 157:339–47.
65. Consolaro A, Ruperto N, Pistorio A, Lattanzi B, Solari N, Galasso R, et al. Development and initial validation of composite parent- and child-centered disease assessment indices for juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011; 63:1262–70.
66. Ravelli A. Toward an understanding of the long-term outcome of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004; 22:271–5.